Assessment of oritavancin serum protein binding across species.
Antimicrob Agents Chemother
; 54(8): 3481-3, 2010 Aug.
Article
em En
| MEDLINE
| ID: mdl-20498314
ABSTRACT
Biophysical methods to study the binding of oritavancin, a lipoglycopeptide, to serum protein are confounded by nonspecific drug adsorption to labware surfaces. We assessed oritavancin binding to serum from mouse, rat, dog, and human by a microbiological growth-based method under conditions that allow near-quantitative drug recovery. Protein binding was similar across species, ranging from 81.9% in human serum to 87.1% in dog serum. These estimates support the translation of oritavancin exposure from nonclinical studies to humans.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Proteínas Sanguíneas
/
Glicopeptídeos
/
Antibacterianos
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Antimicrob Agents Chemother
Ano de publicação:
2010
Tipo de documento:
Article
País de afiliação:
Canadá